We use cookies to provide you with a better experience. By clicking the Accept button, you are agreeing to our use of cookies in accordance with our Privacy Policy.
  • Patient Resources
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
    • Glossary
  • Professional Resources
    • Research Center Profiles
    • Industry Provider Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
  • About Us
  • Contact Us
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » The economics of off-shoring clinical trials

The economics of off-shoring clinical trials

May 9, 2011
CenterWatch Staff

The drugs industry insists that the same strict standards apply to foreign trials as to those conducted domestically, according to a Reuters report.

"We have exactly the same protocol and exactly the same standards for our trials around the world,'' says Roche Holding chief executive Severin Schwan.  "Some years ago quality might have been a real concern. Today the situation is different. This is a reason why more trials are being conducted in emerging markets.''

Switzerland-based Roche, the world's largest maker of cancer drugs, is also conducting more trials overseas because the healthcare authorities in certain countries to see data collected from their own populations.

"I see this as an opportunity. A broader range of patients can take part in our trials and the patient population of our trials becomes ethnically more diverse ... If we do not include a certain portion of patients in our global trials, some countries might delay the approval of certain drugs,'' Schwan says.

However, for drug companies looking to globalize clinical trials, two factors are considered: time and money. The clock is always ticking down to the next drug patent expiration, and taking six months off drug development timelines can spell hundreds of millions of dollars of extra sales.

So, many in the industry are still working out just how much cheaper it really is to do clinical research in internationally.

In 2008, former GlaxoSmithKline chief executive Jean-Pierre Garnier published estimates in an article for the Harvard Business Review, stating a midsize company with 60,000 patients in clinical trials could save $600 million a year by switching 50% of its trials to low-cost places such as India and Latin America.

Kenneth Getz, senior research fellow at the Tufts Center for the Study of Drug Development in Boston, says that in practice things are a bit different. Getz believes off-shoring clinical research is not exactly the bargain many drugmakers anticipated. He considers the per patient cost of running a trial in India or China is probably about half what it would be in Western Europe or the U.S.  While it is a big margin, it is considerably less than Garnier had suggested. And then there is the extra cost of managing multiple studies across multiple sites.

"The economics are not nearly as attractive as once thought,'' Getz says. "Clearly, companies want to test their drugs in markets where they hope to commercialize a new treatment, so that is a driver for deciding where to conduct clinical studies. But given the increased operating costs and the inefficiencies, which can sometimes result in delays in some parts of the world, I think companies will begin to rethink just how many countries they wish to use.''
Global News Study Conduct

Upcoming Events

  • 09Dec

    The Age of eSource: Modernizing Clinical Trials

  • 16Dec

    Master the Regulatory Pathway for Cell & Gene Therapy Submissions: Strategies for Successful BLAs

Featured Products

  • Regenerative-medicine-steps-to-accelerate-development-pdf

    Regenerative Medicine: Steps to Accelerate Development — PDF

  • Clinical-trial-agreements-a-guide-to-key-words-and-phrases-pdf

    Clinical Trial Agreements: A Guide to Key Words and Phrases — PDF

Featured Stories

  • Patient-phsyician-consultation

    Giving Patients Back Their Voice in Clinical Trials

  • Ich_logo

    ICH Overhauls 22-Year-Old Clinical Studies Guideline

  • Survey_chart2019

    Sponsors, CROs Doing Better, Sites Say, But More Work Is Needed

New!

2019 Site Survey Reports

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing